Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 2/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093531 | 1.00 | BCHE (0.51) | BCHEGNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL25094726 | 0.98 | BCHE (0.49) | BCHEGNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL16511590 | 0.94 | EPHX1 (0.49) | BCHEGNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL13207267 | 0.94 | EPHX1 (0.49) | BCHEGNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL6980363 | 0.87 | LTA4H (0.50) | LTA4HEPHX1EPHX2 | |
| SCHEMBL13102170 | 0.87 | LTA4H (0.50) | LTA4HEPHX1EPHX2 | |
| SCHEMBL172561 | 0.87 | LTA4H (0.50) | LTA4HEPHX1EPHX2 | |
| SCHEMBL3821802 | 0.81 | EPHX1 (0.49) | BCHEGNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL26836340 | 0.81 | LTA4H (0.50) | LTA4HKCNH2HTR4 | |
| SCHEMBL8280845 | 0.80 | CA1 (0.47) | LTA4HEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | BCHE 4630/4885GNAI3 190/4885GNAO1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.